Automatic Immunoassay Analyzer Market Segmentation:
Product Type Segment Analysis
The chemiluminescence immunoassay segment is expected to garner the largest share of 48.5% in the market by the end of 2037. The dominance of the segment is attributable to its enhanced sensitivity, speed, and automation compatibility, making it standard for high-volume diagnostic testing. Further, this technology provides users with reduced detection limits when compared to traditional ELISA, thereby enabling quick disease detection, especially in the case of infectious diseases and cancer. NIH clinical study found CLIA is an affordable solution in automated systems, reducing labor costs and human error, remarkably improving workflow efficiency.
Application Segment Analysis
The infectious diseases segment is anticipated to capture the second-largest share of 35.3% in the market during the assessed timeframe. The growth in the segment is highly subject to the pandemic threats, i.e., increasing antibiotic resistance and the need for rapid diagnostics. Besides, WHO data in 2023 notes that the expanded access to high-sensitivity immunoassays for conditions such as COVID-19, influenza, and emerging pathogens enables quick and reliable results. Further, the U.S. FDA is extending its support with clearance for CLA-based tests such as multiplex panels for respiratory and tropical diseases, improving the profitability of the segment.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Product Type |
|
|
Application |
|
|
End user |
|
